Notch1 siRNA and AMD3100 Ameliorate Metabolic Dysfunction-Associated Steatotic Liver Disease

Area of Science:

• Hepatology
• Immunology
• Pharmacology

Background:

• Metabolic dysfunction-associated steatotic liver disease (MASLD) progression involves inflammation, fibrosis, and immune cell dysfunction.
• Targeting the Notch1 pathway and inflammatory cell migration presents a potential therapeutic strategy for MASLD.
• Developing effective MASLD treatments is challenging due to disease complexity and multi-organ crosstalk.

Purpose of the Study:

• To investigate the efficacy of a combination therapy involving Notch1 siRNA and AMD3100 for treating MASLD.
• To evaluate the impact of this combination therapy on macrophage phenotype, inflammation, and liver fibrosis.
• To explore the potential of this approach as a novel therapeutic intervention for MASLD.

Main Methods:

• Developed a combination therapy using Notch1 siRNA (siNotch1) to block the Notch pathway and AMD3100 to inhibit inflammatory cell migration.
• Investigated the effects of siNotch1 and AMD3100 on macrophage phenotype, inflammation, and the CXCL12/CXCR4 axis in liver fibrosis models.
• Conducted in vivo pharmacodynamic studies to assess the therapeutic efficacy of the combination therapy compared to monotherapy in MASLD models.

Main Results:

• The combination therapy modulated macrophages by downregulating Notch-related pathways, reducing inflammation, and promoting a beneficial phenotype switch.
• siNotch1 and AMD3100 inhibited neutrophil extracellular trap (NET) release, further influencing macrophage phenotype.
• In vivo studies demonstrated superior therapeutic effects of the combination therapy over monotherapy in resolving inflammation and MASLD progression.

Conclusions:

• The developed siRNA and small molecule combination therapy effectively targets inflammation and liver injury in MASLD.
• This approach offers a promising therapeutic intervention by modulating macrophage function and inhibiting key fibrotic pathways.
• The findings support a novel therapeutic strategy for MASLD, addressing its complex pathogenesis.